ASCO: Legend/J&J Explore Carvykti In Community
Data Show FHR Myeloma Efficacy
The companies presented data from CARTITUDE-4 in functional high-risk disease, which has a poorer prognosis, while they are also piloting a program to expand Carvykti’s geographic reach.
